SUBSCRIBE
SUBSCRIBE
Tristan Manalac

Tristan Manalac

Contributing Writer | News

Tristan is an independent science writer based in Metro Manila, with more than eight years of experience writing about medicine, biotech and science. Being formally trained in molecular biology, he once dreamed of collecting degrees and starting his own lab. But these days, he finds his greatest joy in a bottle of beer and a beautiful sentence. He can be reached at tristan.manalac@biospace.com, tristan@tristanmanalac.com or on LinkedIn.

Pictured: J&J's office in Madrid, Spain
Drug Development
J&J Gets Phase II Win for First Targeted Oral Peptide in Plaque Psoriasis
Johnson & Johnson’s Protagonist-partnered oral psoriasis candidate was able to sustain its therapeutic benefit through one year, according to data presented on Saturday at the American Academy of Dermatology annual meeting.
March 11, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: Eli Lilly's headquarters in Indianapolis
Policy
Lilly’s Donanemab Hit with Surprise Delay, Set to Face FDA Adcomm
The FDA will convene its Peripheral and Central Nervous System Drugs Advisory Committee to discuss Eli Lilly’s application for its Alzheimer’s disease antibody donanemab, the company announced Friday.
March 8, 2024
 · 
3 min read
 · 
Tristan Manalac
Pictured: Infant in the hospital wearing a ventila
Drug Development
AstraZeneca, Sanofi’s Beyfortus 90% Effective at Preventing RSV Hospitalizations: CDC
AstraZeneca and Sanofi’s respiratory syncytial virus immunizing antibody Beyfortus reached effectiveness of 90% against infection-related hospitalization in infants, according to the Centers for Disease Control and Prevention.
March 8, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: The inside of a federal courtroom/iStock
Policy
NJ Federal Judge Skeptical of Pharma’s Challenge to IRA Drug Price Negotiations
Judge Zahid Quraishi on Thursday appeared unconvinced by the pharmaceutical companies’ arguments that the Inflation Reduction Act’s Drug Price Negotiation Program violated the U.S. Constitution.
March 8, 2024
 · 
2 min read
 · 
Tristan Manalac
FDA signage at its office in Maryland
FDA
BeiGene Secures Fifth Approval for Brukinsa, Expands into Follicular Lymphoma
BeiGene’s Brukinsa becomes the first BTK inhibitor approved for follicular lymphoma, the most common type of low-grade non-Hodgkin lymphoma.
March 8, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: A scientist with pill bottles in front o
Policy
FDA Action Alert: Mirum, BMS, Madrigal and More
The FDA’s busy week ahead involves three decision dates for potential industry firsts and a highly anticipated advisory committee meeting for two CAR-T therapies.
March 7, 2024
 · 
6 min read
 · 
Tristan Manalac
Facade of Novo Nordisk's office in Fremont, California
Drug Development
Novo Touts Phase I Data for Next-Generation Obesity Candidate
Novo Nordisk’s early-stage amylin and GLP-1 co-agonist elicited a 13.1% reduction in body weight, with an overall favorable safety profile, the Danish drugmaker reported Thursday at an investor event.
March 7, 2024
 · 
2 min read
 · 
Tristan Manalac
External view of AstraZeneca's production plant in Sweden
Drug Delivery
AstraZeneca Invests $827M in UK Footprint, Focuses on Vaccine Manufacturing and R&D
The Anglo-Swedish drugmaker is making the investment to bolster its vaccine manufacturing and research and development capabilities in the U.K.
March 7, 2024
 · 
2 min read
 · 
Tristan Manalac
Front view of the White House
Policy
Biden Calls for Expanding IRA’s Drug Price Negotiation Program
President Joe Biden has proposed expansions to the Inflation Reduction Act, including an increase in the annual number of prescription drugs that would be subject to price negotiations to 50, up from 20.
March 7, 2024
 · 
4 min read
 · 
Tristan Manalac
Pictured: Nasdaq signage and building in New York City
Deals
Cancer-Focused Boundless Bio to Go Public as 2024 IPO Rally Continues
The early-stage oncology startup filed for an initial public offering on Wednesday, seeking funds to help develop its novel cancer therapies targeting extrachromosomal DNA.
March 7, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: WHO headquarters in Geneva, Switzerland/
WHO Warns of Growing Resistance in Individuals to GSK, ViiV’s HIV Drug Tivicay
The World Health Organization has detected signals of growing HIV resistance to GSK and ViiV Healthcare’s Tivicay, which it says must be minimized as part of the broader global response to antimicrobial resistance.
March 6, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: FDA signage at its office in Washington, DC
FDA
Sandoz Nabs FDA Approvals for First Two Biosimilars for Amgen’s Denosumab
Sandoz’s two interchangeable biosimilars, Jubbonti and Xgeva, are poised to challenge Amgen’s blockbuster bone drug denosumab. However, no launch details were announced Tuesday due to ongoing patent litigation.
March 6, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: NHS sign on a building/iStock, TkKurikaw
Policy
UK’s NICE Rejects AstraZeneca, Daiichi Sankyo’s Enhertu for NHS Use
Despite its overall survival and disease progression benefits, the U.K.’s drug cost watchdog has declined to recommend AstraZeneca and Daiichi Sankyo’s Enhertu due to a lack of cost-effectiveness.
March 6, 2024
 · 
2 min read
 · 
Tristan Manalac
Novo Nordisk's corporate headquarters in Denmark
Drug Development
Novo’s Ozempic Poised for Cardiometabolic Expansion with New Phase III Data
After stopping the study early due to strong efficacy, Novo Nordisk released data from the FLOW study showing significant benefits of semaglutide in patients with type 2 diabetes and chronic kidney disease.
March 5, 2024
 · 
2 min read
 · 
Tristan Manalac
FDA signage at its office in Maryland
FDA
Eyenovia, Formosa Win FDA Approval for Anti-Inflammatory Eye Drops
The regulator has approved Eyenovia and Formosa’s ophthalmic clobetasol propionate solution to ease eye inflammation and pain after surgery, with a potential $1.3 billion market.
March 5, 2024
 · 
2 min read
 · 
Tristan Manalac
Load More